According to the National Cancer Institute, approximately 64,000 patients will be diagnosed with renal and pelvis cancer this year and 14,500 may die due to the disease. Therefore, there is a great need to prevent the cancer recurrence and improve the quality of life in these patients. In this regard, The U.S. Food and Drug Administration recently approved Sunitinib malate as an adjuvant treatment for adult patients who have undergone nephrectomy and are at a high risk of renal cell carcinoma.
Sunitinib malate is the first adjuvant treatment approved for patients with renal cell carcinoma, who previously did not have options to potentially reduce cancer recurrence. Sunitinib malate is a kinase inhibitor that works by blocking several enzymes that promote cell growth. It was first approved in 2006 for the treatment of certain patients with gastrointestinal stromal tumors and advanced…
